Preclinical CRO Admescope acquires MetaSafe to up drug metabolism services

By Melissa Fassbender contact

- Last updated on GMT

(Image: Getty/Kritchanut)
(Image: Getty/Kritchanut)
The preclinical contract research organization (CRO) Admescope has acquired MetaSafe in a deal which will bolster its drug metabolism services for clinical phase projects.

Admescope – a Oulu, Finland-headquartered company providing absorption, distribution, metabolism, and excretion (ADME) and toxicology services – yesterday announced its acquisition of the CRO MetaSafe.

Based in Södertälje, Sweden, MetaSafe focuses on metabolite identification studies during drug development.

Juho Alatalo, VP of marketing and sales at Admescope told us the acquisition broadens the company’s services for clinical stage metabolism studies.

The deal – financial terms of which were not disclosed – also expands Admescope's physical presence to Stockholm area, providing a larger recruitment pool to support future growth, Alatalo explained.

For the near future, Metasafe AB will operate as a fully owned subsidiary of Admescope, shifting to operate under Admescope brand at autumn,”​ he added.

The companies will immediately start aligning research procedures "and other practical matters."

"We are very excited about the acquisition and to welcome the experienced experts of ​Metasafe to Admescope,"​ Alatalo added. "We are certain that this acquisition will help us serve all of our customers even better, offering a broader portfolio of services for their projects at clinical stages."

Related news

Show more

Related products

show more

Stability Testing As a Quality Control Measure

Stability Testing As a Quality Control Measure

Frontage Laboratories | 19-Jun-2019 | Technical / White Paper

Stability testing is, in essence, a quality control process and is there¬fore a vital component of every phase of clinical development for both large and...

Leveraging Best Practices in Primary Packaging

Leveraging Best Practices in Primary Packaging

Catalent Pharma Solutions | 05-Mar-2018 | Technical / White Paper

When planning a clinical trial, overlooking the importance of primary packaging can be a mistake. From stability concerns to labeling to patient compliance...

Ocopeptides

Advancing therapeutics for myeloma

Recipharm AB | 04-Sep-2017 | Case Study

Multiple myeloma is the second most common blood cancer in the world and despite survival rates increasing over the last decade, there remains a requirement...

Related suppliers

Follow us

Products

View more

Webinars